MXPA03008820A - Compuestos generadores de monoxido de carbono, para el tratamiento de desordenes vasculares, inflamatorios e inmunologicos. - Google Patents

Compuestos generadores de monoxido de carbono, para el tratamiento de desordenes vasculares, inflamatorios e inmunologicos.

Info

Publication number
MXPA03008820A
MXPA03008820A MXPA03008820A MXPA03008820A MXPA03008820A MX PA03008820 A MXPA03008820 A MX PA03008820A MX PA03008820 A MXPA03008820 A MX PA03008820A MX PA03008820 A MXPA03008820 A MX PA03008820A MX PA03008820 A MXPA03008820 A MX PA03008820A
Authority
MX
Mexico
Prior art keywords
inflammatory
treatment
carbon monoxide
inhibiting
vascular
Prior art date
Application number
MXPA03008820A
Other languages
English (en)
Inventor
Woo Jacky
Original Assignee
Sangstat Medical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sangstat Medical Corp filed Critical Sangstat Medical Corp
Publication of MXPA03008820A publication Critical patent/MXPA03008820A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se suministran metodos y composiciones para tratar enfermedades vasculares y modular los procesos inflamatorios e inmunologicos, con el uso de compuestos que generan monoxido de carbono, que incluyen el cloruro de metileno. Los presentes compuestos son capaces de inhibir la proliferacion de las celulas vasculares de los musculos lisos, proteger la vasculatura contra tensiones y lesiones oxidantes, modular la actividad de varias celulas del sistema inmunologico, inhibir las citocinas pro-inflamatorias y aumentar la produccion de citocinas anti-inflamatorias, siendo asi efectivos en el tratamiento de condiciones asociadas con las respuestas adversas proliferativas o inflamatorias. Tambien se suministran metodos para prolongar la sobrevivencia de un transplante de organo e inhibir el rechazo cronico en un receptor.
MXPA03008820A 2001-03-30 2002-04-01 Compuestos generadores de monoxido de carbono, para el tratamiento de desordenes vasculares, inflamatorios e inmunologicos. MXPA03008820A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28052601P 2001-03-30 2001-03-30
PCT/US2002/010115 WO2002078684A2 (en) 2001-03-30 2002-04-01 Carbon monoxide generating compounds for treatment of vascular, inflammatory and immune disorders

Publications (1)

Publication Number Publication Date
MXPA03008820A true MXPA03008820A (es) 2004-07-30

Family

ID=23073455

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03008820A MXPA03008820A (es) 2001-03-30 2002-04-01 Compuestos generadores de monoxido de carbono, para el tratamiento de desordenes vasculares, inflamatorios e inmunologicos.

Country Status (9)

Country Link
US (1) US20030068387A1 (es)
EP (1) EP1381354A2 (es)
JP (1) JP2004526739A (es)
CN (1) CN1507348A (es)
CA (1) CA2442457A1 (es)
IL (1) IL158182A0 (es)
MX (1) MXPA03008820A (es)
RU (1) RU2003131675A (es)
WO (1) WO2002078684A2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8128963B2 (en) 1996-09-27 2012-03-06 The Trustees Of Columbia University In The City Of New York Methods for treating ischemic disorders using carbon monoxide
US7678390B2 (en) 1999-04-01 2010-03-16 Yale University Carbon monoxide as a biomarker and therapeutic agent
GB0111872D0 (en) 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
ATE413883T1 (de) * 2001-06-21 2008-11-15 Beth Israel Hospital Kohlenmonoxid verbessert die ergebnisse bei gewebe- und organtransplantationen und unterdrückt apoptose
CA2475209A1 (en) 2002-02-04 2003-08-14 Alfama - Investigacao E Desenvolvimento De Produtos Farmaceuticos Lda. Use of co-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases
US7968605B2 (en) * 2002-02-04 2011-06-28 ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
US20080026984A1 (en) * 2002-02-04 2008-01-31 Alfama - Investigacao E Desenvolvimento De Productos Farmaceuticos Lda Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
WO2003072024A2 (en) 2002-02-13 2003-09-04 Beth Israel Deaconess Medical Center, Inc. Methods of treating vascular disease
AU2003226366A1 (en) 2002-04-15 2003-11-03 Beth Israel Deaconess Medical Center Use of heme oxygenase-1 and products of heme degradation
JP4588325B2 (ja) * 2002-04-15 2010-12-01 ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション イレウスの治療方法
JP4585765B2 (ja) * 2002-04-15 2010-11-24 ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 壊死性腸炎の治療方法
AU2002308676B2 (en) * 2002-05-09 2009-06-11 Johns Hopkins University Carbon monoxide as a biomarker and therapeutic agent
ES2372273T3 (es) * 2002-05-17 2012-01-17 Yale University Métodos de tratamiento de la hepatitis.
RS105304A (en) * 2002-06-05 2007-02-05 Yale University, Methods of treating angiogenesis,tumor growth,and metastasis
CN1674942A (zh) * 2002-06-21 2005-09-28 联邦高等教育系统匹兹堡大学 氧化氮、血红素加氧酶－1和血红素降解产物的药学用途
RS20050344A (en) * 2002-11-07 2007-11-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education, Treatment for hemorrhagic shock
GB2395432B (en) * 2002-11-20 2005-09-14 Northwick Park Inst For Medica Therapeutic delivery of carbon monoxide to extracorporeal and isolated organs
US20070207217A1 (en) * 2003-02-03 2007-09-06 Alfama - Investigacao E Desenvolvimento De Productos Farmaceuticos Lda Method for treating a mammal by administration of a compound having the ability to release CO
WO2007073225A1 (en) * 2005-12-20 2007-06-28 Alfama - Investigação E Desenvolvimento De Produtos Farmacêuticos Lda. Molybdenum carbonyl complexes for treating rheumatoid arthritis and other inflammatory diseases
GB0601394D0 (en) 2006-01-24 2006-03-01 Hemocorm Ltd Therapeutic delivery of carbon monoxide
JP5020525B2 (ja) * 2006-03-30 2012-09-05 財団法人生産開発科学研究所 配位子置換型輸液製剤
WO2008130261A1 (en) * 2007-04-24 2008-10-30 Alfama - Investigaçao E Desenvolvimento De Produtos Farmaceuticos Lda. Treatment of infections by carbon monoxide
US8778413B2 (en) * 2010-05-14 2014-07-15 Ikaria, Inc. Dosing regimens and methods of treatment using carbon monoxide
ES2656237T3 (es) 2011-04-19 2018-02-26 Alfama, Inc. Moléculas liberadoras de monóxido de carbono y usos de las mismas
JP6134710B2 (ja) 2011-07-21 2017-05-24 アルファーマ インコーポレイテッドＡｌｆａｍａ，Ｉｎｃ． 一酸化ルテニウム放出分子およびその使用
JP2014525399A (ja) 2011-08-09 2014-09-29 ベス・イスラエル・ディーコネス・メディカル・センター，インコーポレイテッド Ｄｎａ損傷を処置する方法
CN105288599A (zh) * 2015-10-22 2016-02-03 徐州医学院 血红素氧化酶-2在制备抑制器官移植免疫排斥制剂中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995013082A1 (en) * 1993-11-08 1995-05-18 Pharmagenesis, Inc. Immunotherapy composition and method

Also Published As

Publication number Publication date
WO2002078684A3 (en) 2002-12-19
IL158182A0 (en) 2004-03-28
JP2004526739A (ja) 2004-09-02
CN1507348A (zh) 2004-06-23
RU2003131675A (ru) 2005-03-10
CA2442457A1 (en) 2002-10-10
EP1381354A2 (en) 2004-01-21
WO2002078684A2 (en) 2002-10-10
US20030068387A1 (en) 2003-04-10

Similar Documents

Publication Publication Date Title
MXPA03008820A (es) Compuestos generadores de monoxido de carbono, para el tratamiento de desordenes vasculares, inflamatorios e inmunologicos.
IL267381A (en) A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders
IL245146A0 (en) Phosphatidyl-inositol 3-kinase delta inhibitors
ATE406909T1 (de) Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
DK0786991T3 (da) Polyaminforbindelsre til behandling af proliferative karsygdomme
ATE439137T1 (de) Behandlung von hämatologischen störungen
MY155218A (en) Small molecules useful in the treatment of inflammatory disease
RS51122B (sr) Primena 5`-metiltioadenozina(mta) kod prevencije i/ili lečenja autoimunih bolesti i/ili pri odbacivanju transplantata
WO2002058535A3 (en) Use of combretastatin a4 and its prodrugs as an immune enhancing therapy
WO2000000634A3 (en) METHODS OF INHIBITING $i(HELICOBACTER PYLORI)
EP0444899A3 (en) Catechol derivatives, their physiologically acceptable salts, esters and their use in the treatment of tissue damage induced by lipid peroxidation
WO2004031347A3 (en) Methods and compositions for soluble cpg15
TW200501958A (en) A therapeutic agent for treating a behavioral disorder
WO2006047198A3 (en) Composition and method for using a cytokine to treat restenosis
WO2001016358A3 (en) Method of screening for triacyglycerol hydrolase inhibitors
GT199300033A (es) Procedimiento para la preparacion de un derivado indol
UA33498A (uk) Спосіб лікування терапевтично резистентних форм шизофренії
UA88600C2 (ru) Фармацевтическая стандартная доза модафинила и способ лечения adhd